1 The Cancer Research Chair, Department of Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
2 Department of Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
3 Department of Urology, king Faisal specialist hospital and research Center, Riyadh, Saudi Arbia.
International Journal of Science and Research Archive, 2025, 14(03), 890-893
Article DOI: 10.30574/ijsra.2025.14.3.0759
Received on 09 February 2025; revised on 14 March 2025; accepted on 17 March 2025
Prostate cancer (PCa) is an emerging public health concern in Saudi Arabia, with increasing incidence and significant challenges in early detection and management. This review summarizes current research on PCa in Saudi Arabia, covering its incidence, risk factors, treatment outcomes, screening practices, awareness, and recent advancements. We aim to offer a thorough understanding to healthcare professionals, policymakers, and the public. Data from observational studies, cancer registries, and clinical guidelines published between 2008 and 2024 were also reviewed. The incidence of prostate cancer is rising, with 752 new cases by 2022; however, it remains lower than that in Western countries. High metastasis rates at diagnosis (31.4%) and low screening uptake contribute to poor outcomes, with a 5-year survival rate of 49%. Treatment aligns with international standards; however, awareness and early detection lag. Enhanced screening and education are recommended to improve prognosis.
Prostate cancer; Epidemiological trends; Risk factors; Treatment outcomes; Screening practices
Preview Article PDF
Karim Hamda Farhat, Abdulaziz Mohammed Althunayan and Danny Munther Rabah. Research analysis of prostate cancer in Saudi Arabia. International Journal of Science and Research Archive, 2025, 14(03), 890-893. Article DOI: https://doi.org/10.30574/ijsra.2025.14.3.0759.
Copyright © 2025 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
